Compare Inovio Pharmaceuticals Inc (INO) vs Janus Living Inc. Class A-1 Common Stock (JAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Janus Living Inc. Class A-1 Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.18 (market cap $103.19M), while Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.76B). The key difference: Janus Living Inc. Class A-1 Common Stock is far larger — about 65.5× Inovio Pharmaceuticals Inc's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Janus Living Inc. Class A-1 Common Stock for 0 Days on average.
| INO | JAN | |
|---|---|---|
Market Cap | $103.19M | $6.76B |
Volume | 8,461,580 | 1,332,082 |
Sector | Health | Real Estate |
52-Week High | $2.60 | $31.76 |
52-Week Low | $0.66 | $22.88 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $6.85B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →
